Table 1 Clinicopathologic characteristics of TAX 307S stratified by treatment (TAC vs.FAC)
Treatment group | |||
|---|---|---|---|
Variable | FAC1 (n = 54) | TAC2 (n = 54) | P* |
Menopausal status | Â | Â | Â |
   Premenopausal | 9 (16.7) | 15 (27.8) | 0.119 |
   Postmenopausal | 36 (66.7) | 28 (51.9) |  |
   Other | 9 (16.7) | 11 (20.4) |  |
Tumor size (cm) | Â | Â | Â |
   ≤ 2 | 9 (16.7) | 15 (27.8) | 0.216 |
   2-5 | 29 (53.7) | 27 (50.0) |  |
   ≥ 5 | 12 (22.2) | 10 (18.5) |  |
   Other | 4 (7.4) | 2 (3.7) |  |
Nodal status | Â | Â | Â |
   Negative for node metastasis | 16 (29.6) | 17 (31.5) | 0.874 |
   Positive for node metastasis | 29 (53.7) | 33 (61.1) |  |
   Other | 9 (16.7) | 4 (7.4) |  |
Histology | Â | Â | Â |
   Infiltrating ductal carcinoma | 43 (79.6) | 46 (85.2) | 0.800 |
   Infiltrating lobular carcinoma | 5 (9.3) | 5 (9.3) |  |
   Other | 6 (11.1) | 3 (5.6) |  |
Tumor grade | Â | Â | Â |
   Well/moderately differentiated | 18 (33.3) | 13 (24.1) | 0.148 |
   Poorly/undifferentiated | 27 (50.0) | 32 (59.3) |  |
   Other | 4 (7.4) | 1 (1.9) |  |
   Unknown | 5 (9.3) | 8 (14.8) |  |
ER status | Â | Â | Â |
   ER negative | 18 (33.3) | 22 (40.7) | 0.398 |
   ER positive | 27 (50.0) | 23 (42.6) |  |
   Other | 9 (16.7) | 9 (16.7) |  |
PR status | Â | Â | Â |
   PR negative | 19 (35.2) | 22 (40.7) | 0.458 |
   PR positive | 25 (46.3) | 21 (38.9) |  |
   Other | 10 (18.5) | 11 (20.4) |  |
Prior adjuvant chemotherapy | Â | Â | Â |
   No therapy | 29 (53.7) | 26 (48.1) | 0.565 |
   Yes therapy | 25 (46.3) | 28 (51.9) |  |
Prior adjuvant hormonal therapy | Â | Â | Â |
   No therapy | 31 (57.4) | 40 (74.1) | 0.070 |
   Yes therapy | 23 (42.6) | 14 (25.9) |  |
Prior metastatic hormonal therapy | Â | Â | Â |
   No therapy | 39 (72.2) | 41 (75.9) | 0.662 |
   Yes therapy | 15 (27.8) | 13 (24.1) |  |
Response to therapy | Â | Â | Â |
   Complete response (CR) | 3 (5.6) | 5 (9.3) | 0.5844 |
   Partial response (PR) | 25 (46.3) | 23 (42.6) |  |
   Stable disease (SD) | 15 (27.8) | 14 (25.9) |  |
   Progressive disease (PD) | 9 (16.7) | 7 (13.0) |  |
   Other | 2 (3.7) | 5 (9.3) |  |